









Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/845,716
		Filing Date	May 2, 2001
		First Named Inventor	Soren NIELSEN
		Group Art Unit	1647
		Examiner Name	DeBerny
Sheet 1	of 2	Attorney Docket Number	NIELSEN3A

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number known)	Kind Code ² (if			
	AA	5 0 2 8 5 9 2		LIPTON	07-02-1991	
	AB	5 7 3 1 4 0 8		HADLEY, et al.	03-24-1998	
	AC	5 8 3 0 9 9 4		D'HINTERLAND, et al.	11-03-1998	
	AD	5 8 3 5 3 8 2		WILSON, et al.	11-10-1998	
	AE	5 9 8 6 0 4 7		WRIGHTON, et al.	11-16-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	U.S. Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Office ³	Number	Kind Code ⁵ (if known)				
ky	AF	WO	8 7 0 4 6 2 3		UNIVERSITY PATENTS INC.	08-13-1987		
	AG	WO	8 8 0 0 8 3 3		BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	02-11-1988		
	AH	WO	9 6 4 1 8 1 5		DUSSOURD D'HINTERLAND	12-27-1996		
	AI	WO	9 9 2 1 5 7 1		TREGA BIOSCIENCES, INC.	05-06-1999		
	AJ	WO	9 9 5 7 1 4 8		WA PHARM AB	11-11-1999		
	AK	WO	0 0 3 2 7 7 2		ELI LILLY AND CO.	06-08-2000		
ky	AL	EP	0 9 7 2 5 2 2		L'OREAL-DPI	01-19-2000		

Examiner Signature	<i>Regina M. DeBerny</i>	Date Considered	11/10/05
--------------------	--------------------------	-----------------	----------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) OCT 01 2001 35 U.S.C. 112 TRADEMARK OFFICE		Application Number	09/845,716
		Filing Date	May 2, 2001
		First Named inventor	Soren NIELSEN
		Group Art Unit	1647
		Examiner Name	DeBerry
Sheet 2	of 2	Attorney Docket Number	NIELSEN 3A

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
AM	RAJORA, et al., α -MSH Modulates Experimental Inflammatory Bowel Disease, Peptides, 1997, 381-385, 18(3)		
AN	STAR, et al., Evidence of Autocrine Modulation of Macrophage Nitric Oxide Synthase by α -melanocyte-stimulating Hormone, Proc. Natl. Acad. Sci. USA, 1995, 8016-8020, 92		
AO	SADAMOTO, et al., Erythropoietin Prevents Place Navigation Disability and Cortical Infarction in Rats with Permanent Occlusion of the Middle Cerebral Artery, Biochemical and Biophysical Research Communications, 1998, 26-32, 253		
AP	SAKANAKA, et al., <i>In vivo</i> Evidence that Erythropoietin Protects Neurons from Ischemic Damage, Proc. Natl. Acad. Sci. USA, 1998, 4635-4640, 95		
AQ	SQUADRITO, et al., Recombinant Human Erythropoietin Inhibits iNOS Activity and Reverts Vascular Dysfunction in Splanchnic Artery Occlusion Shock, British Journal of Pharmacology, 1999, 482-488, 127		
AR	SQUADRITO, et al., Adrenocorticotropin Reverses Vascular Dysfunction and Protects Against Splanchnic Artery Occlusion Shock, British Journal of Pharmacology, 1999, 816-822, 128		
AS	CHIAO, et al., α -Melanocyte-stimulating Hormone Protects Against Renal Injury after Ischemia in Mice and Rats, J. Clin. Invest., 1997, 1165-1172, 99(6)		

Examiner Signature	<i>Regina M. H. B.</i>	Date Considered	1/10/05
--------------------	------------------------	-----------------	---------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.